Inogen sees slight stock climb behind regulatory wins
Goleta-based Inogen saw its stock climb about 3% after the company achieved regulatory milestones in the European Union and the United States to support its products and shared its preliminary fourth quarter and full-year revenue results on Jan. 10. Inogen, a maker of portable oxygen containers, received European Medical Device Regulation certification from the British Read More →
Westlake Village Biopartners’ backed Acelyrin makes first acquisition
Acelyrin, a Los Angeles-based biotechnology company, announced its first acquisition of ValenzaBio, a privately held company developing therapies for autoimmune and inflammatory diseases, in an all-stock transaction, the company said Jan. 5. With the acquisition, Acelyrin gains multiple clinical and pre-clinical development programs to its robust immunology pipeline, which is led by izokibep, a small Read More →
Arcutis approves equity grants
Westlake Village-based Arcutis Biotherapeutics announced the grant of an aggregate of 17,050 restricted stock units of Arcutis’ common stock as well as options to purchase an aggregate of 33,550 shares of Arcutis’ common stock to five newly hired employees. The stock options have a ten-year term and an exercise price of $14.77 per share, equal to Read More →
Mercado: Central Coast’s unique technology landscape will continue thrive in 2023
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Technology Forecast: Innovation will be the theme for 2023
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Capsida announces multi-year agreement with Eli Lilly subsidiary
Thousand Oaks-based Capsida Therapeutics has entered into a multi-year agreement with Prevail Therapeutics, a wholly owned subsidiary of Eli Lilly and Company, to develop transformative genetic medicines for serious diseases, Capisda announced Jan. 4. As per the agreement, Capsida will receive $55 million in the form of an upfront payment and a commitment to participate Read More →
O’Dowd’s fight against Tesla, Musk continues
Elon Musk has been making headlines, mostly at his expense, nearly every day since his $44 billion purchase of Twitter. But for Dan O’Dowd, Musk’s Tesla software is no laughing matter. It has been nearly a year since Dan O’Dowd took out his first full-page newspaper advertisement, highlighting his disdain for Tesla’s assisted-driving technology. But the Read More →
